<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22673234</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-7445</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>72</Volume>
                    <Issue>16</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer research</Title>
                <ISOAbbreviation>Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3948-57</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-11-4134</ELocationID>
            <Abstract>
                <AbstractText>The transcription factor p53 regulates genes associated with a wide range of functions, including the Toll-like receptor (TLR) set of innate immunity genes, suggesting that p53 also modulates the human immune response. The TLR family comprises membrane glycoproteins that recognize pathogen-associated molecular patterns (PAMP) and mediate innate immune responses, and TLR agonists are being used as adjuvants in cancer treatments. Here, we show that doxorubicin, 5-fluorouracil, and UV and ionizing radiation elicit changes in TLR expression that are cell line- and damage-specific. Specifically, treatment-induced expression changes led to increased downstream cytokine expression in response to ligand stimulation. The effect of DNA stressors on TLR expression was mainly mediated by p53, and several p53 cancer-associated mutants dramatically altered the pattern of TLR gene expression. In all cell lines tested, TLR3 induction was p53-dependent, whereas induction of TLR9, the most stress-responsive family member, was less dependent on status of p53. In addition, each of the 10 members of the innate immune TLR gene family tested was differentially inducible. Our findings therefore show that the matrix of p53 status, chromosome stress, and responsiveness of individual TLRs should be considered in TLR-based cancer therapies.</AbstractText>
                <CopyrightInformation>Â©2012 AACR.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shatz</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Chromosome Stability Group, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences (NIEHS), NIH, Research Triangle Park, North Carolina 27709, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Menendez</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Resnick</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>Z01 ES065079</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ZIA ES065079-18</GrantID>
                    <Acronym>NULL</Acronym>
                    <Agency>Intramural NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>Z01-ES065079.</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>06</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Res</MedlineTA>
            <NlmUniqueID>2984705R</NlmUniqueID>
            <ISSNLinking>0008-5472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012516" MajorTopicYN="N">Osteosarcoma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020218" MajorTopicYN="N">Response Elements</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22673234</ArticleId>
            <ArticleId IdType="pii">0008-5472.CAN-11-4134</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4134</ArticleId>
            <ArticleId IdType="pmc">PMC3443562</ArticleId>
            <ArticleId IdType="mid">NIHMS393796</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2000 Jan;18(2):385-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10637254</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Immunol. 2012;114:177-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22449782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dermatology. 2002;205(2):135-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12218228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12826609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9934-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12909720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2004 Feb 6;303(5659):844-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14704432</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Respir Cell Mol Biol. 2004 Jun;30(6):777-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14656745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2004 Oct;5(10):975-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15454920</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hum Genet. 2004 Nov;75(5):885-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15359380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1991 Jul 5;253(5015):49-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1905840</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 1992 Apr;1(1):45-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1301998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Sep 10;285(5434):1733-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10481009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2005 Jun;5(6):446-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15928677</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S403-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16237638</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2006 Feb 1;176(3):1869-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16424218</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2006 Mar;26(6):2297-308</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16508005</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2006 Apr 15;176(8):4894-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16585585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2006 Aug;7(8):868-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16829963</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):252-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17190817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Immunol. 2007 Feb;19(1):39-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17129718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Immunol. 2007 Feb;19(1):24-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17275323</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Immunol. 2007 May;44(12):3234-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17339052</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 2007 Jun 1;563(1-3):1-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17383632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2007 May;117(5):1184-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17476348</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2007 May;13(5):552-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17479101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Mutat. 2007 Jun;28(6):622-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17311302</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2007 Jul;92(7):2773-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17473064</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2007 Aug 1;179(3):1893-900</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17641056</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2007 Sep;13(9):1050-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17704786</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):944-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18187580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2008 Jul;29(7):1334-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18566014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Genet. 2008 Jun;4(6):e1000104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18714371</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2008 Nov;28(21):6557-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18779317</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Jan;9(1):57-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19052556</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Oct;9(10):691-700</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19759539</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Exp Med Biol. 2009;653:15-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19799109</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1500-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20080630</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2010 May;8(5):701-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20407015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2010 Jul;101(7):1610-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20367642</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunotherapy. 2009 Nov;1(6):949-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20563267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Immunol. 2010 Oct;31(10):391-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20832362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Apr 1;71(7):2466-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21427357</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Genet. 2011 Mar;7(3):e1001360</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21483755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2012 Feb 1;72(3):581-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22158905</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11481490</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>